Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
Journal
Orphanet journal of rare diseases
Journal Volume
18
Journal Issue
1
Pages
289
Date Issued
2023-12
Author(s)
Yu, An-Li
Wu, Yuan-Kun Aden
Chou, Chia-Hung
Abstract
Transthyretin cardiac cardiomyopathy (ATTR-CM) is a rare but life-threatening disease. Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are unknown. This study aimed to used cardiac magnetic resonance (CMR) to investigate the effects of tafamidis on patients with hereditary A97S ATTR-CM.
Subjects
Cardiac magnetic resonance; Extracellular volume; Hereditary transthyretin amyloidosis; Tafamidis
SDGs
Type
journal article